Cingulate Inc. (CINGW)

NASDAQ · Pharmaceuticals & Biotech · Pharmaceutical Preparations

Price
$0.01
Day
-10.45%

Close 2026-09-23.

The company

We are a biopharmaceutical company using our proprietary Precision Timed Release TM (“PTR TM ”) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (“ADHD”) and anxiety, we are identifying and evaluating additional therapeutic areas where our PTR technology may be employed to develop future product candidates. Our PTR platform incorporates a proprietary Erosion Barrier Layer (“EBL”) designed to allow for the release of drug substance at specific, pre-defined time intervals, unlocking the potential for once-daily, multi-dose tablets. We are targeting the ADHD treatment market, with an estimated US market size of approximately 100 million annual prescriptions of stimulants, as of September 2025. Furthermore, the average branded long-acting stimulant wholesale acquisition cost (WAC) is $495/Rx. It is reasonable to assume that a 1% market share capture would represent approximately $250 to $300 million in annual revenue less rebates and discounts in this marketplace. Our two proprietary, first-line stimulant medications: CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), are being developed for the treatment of ADHD across all three patient segments: children (ages 6 -12), adolescents (ages 13-17), and adults (ages 18+).

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

Recent filings